Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Introduction/Background

CV Risk in Patients With T2DM and No Prior MI Similar to Risk in People Without T2DM, but With Prior MI

Comparative Determinants of 4-Year CV Event Rates in Stable Outpatients at Risk of or With Atherothrombosis: REACH Registry

T2DM and Patients at CV Risk

BP Targets in the Context of T2DM Risk

Effect of Aspirin Therapy on Primary Prevention of Major CV Events: Results of a Meta-Analysis

Safety of Glucose-Lowering Agents in T2DM

DPP-4 Inhibitors: Topline Clinical Trial Results

GLP-1 RAs: Topline Clinical Trial Results

SGLT2 Inhibitors: Clinical Trial Results

AEs Associated With TZDs in T2DM

December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

Potential Limitations of T2DM CV Safety Outcomes Trials

SAVOR-TIMI 53 (Saxagliptin): Hospitalization for HF

EXAMINE (Alogliptin): Hospitalization for HF

TECOS (Sitagliptin): Hospitalization for HF

ELIXA (Lixisenatide): Primary Outcome CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for UA

LEADER: Primary Outcome*

EMPA-REG OUTCOME: Trial Design

EMPA-REG Primary Outcome (3-Point MACE): CV Death, Non-Fatal MI, or Non-Fatal Stroke

EMPA-REG: Results for CV Death

EMPA-REG Microvascular Outcomes: Renal Protection

EMPA-REG: Hospitalization for Heart Failure

Potential Mechanisms for CV Benefit Associated With Empagliflozin

Potential Pathways Linking SGLT2 Inhibitor and Reduced Risk of Hospitalization for HF

EMPA-REG Outcomes: Class Effect or Agent Specific?

CDA Treatment Guidelines: 2016 Interim Update SGLT2 Inhibition

Conclusions

Abbreviations

Abbreviations (cont)